Abstract. Progressive supranuclear palsy (PSP) is characterized by specific filamentous tau inclusions present in 3 types of cells including oligodendrocytes (coiled bodies), astrocytes (tufted astrocytes), and neurons (neurofibrillary tangles; NFTs). To correlate the morphological features and biochemical composition of tau in the inclusions, we examined tau filamentenriched fractions isolated from selected brain regions. Frontal and cerebellar white matter manifested a predominance of coiled bodies. The isolated fractions contained straight, 14-nm-wide filaments of relatively smooth appearance. Caudate nucleus and motor cortex with numerous tufted astrocytes contained mostly straight, but irregular, 22-nm-wide filaments with jagged contours. Perirhinal cortex and hippocampus, rich in NFTs, contained 22-nm-wide filaments that were twisted at 80-nm intervals. Among the regions, those with tufted astrocytes showed the most heterogeneity in the ultrastructure of filaments. In all regions, isolated filaments were immunolabeled with PHF-1, Tau 46, and AT8. Fractions from all regions showed 2 PHF-1 immunoreactive bands of 64 and 68 kDa, while an additional band of 60 kDa was detected in NFT-enriched regions. All fractions, in varying extents, showed Tau-1-immunoreactive bands between 45-64 kDa. The results indicate that the 3 types of PSP tau inclusions vary in the ultrastructure although with some overlapping features. Neuronal and glial inclusions also vary in the biochemical profile of tau protein. These differences may depend on the metabolism of tau in the diseased oligodendrocytes, astrocytes, and neurons.
INTRODUCTION
Progressive supranuclear palsy (PSP) is one of the rare neurodegenerative disorders that is clinically characterized by supranuclear ocular palsy, pseudobulbar palsy, parkinsonism with axial dystonia and postural instability, and progressive subcortical dementia (1) (2) (3) . The presence of glial as well as neuronal pathology has recently been highlighted in PSP (4) (5) (6) (7) (8) . The pathological features have been described as abnormal intracellular tau inclusions in specific anatomical areas involving astrocytes, oligodendrocytes, and neurons. Astrocytic pathology is seen in 3 recognizable forms: tufted astrocytes, astrocytic plaques, and thorn-shaped astrocytes. Specific tau-positive astrocytic inclusions in PSP are tufted astrocytes. For example, tufted astrocytes found in frontal lobe (areas 4 and 6) and putamen (6) are highly suggestive of PSP. These are extremely rare in the basal region (temporal lobe and insular cortex) and limbic system (amygdaloid nucleus, cingulate gyrus, and hippocampus). On the other hand, astrocytic plaques are rare in PSP and more common in corticobasal degeneration (CBD) (9, 10) . Thorn-shaped astrocytes are argyrophilic tau-positive astrocytes detected in subpial and subependymal regions of some PSP cases (11) . They resemble reactive astrocytes containing argyrophilic-rich cytoplasm and are mostly located in the vicinity of subpial and perivascular areas corresponding to astrocytic end feet. An unusual type of PSP tau-positive astrocyte has also been reported, resembling the Alzheimer-type 1 glial cell commonly seen in hepatic encephalopathy and Wilson's disease (12) . Tau inclusions seen in oligodendrocytes of PSP are described as coiled bodies and similar structures are detected also in other degenerations, e.g. CBD (13) . Neurofibrillary tangles (NFTs) in PSP resemble either cortical flame-shaped neuronal inclusions as seen in Alzheimer disease (AD) or subcortical globose-shaped inclusions often referred to as globose tangles (4, 14) .
The abnormal tau inclusions are composed of aggregated and highly phosphorylated tau protein, which is a microtubule-associated protein playing a role in microtubule assembly and stability. Normal brain tau contains 6 isoforms, with the 1:1 ratio between isoforms expressing 3 repeats (3Rtau) and 4 repeats (4Rtau) in the microtubule binding domain (15) . The isoforms are generated by the alternative splicing of a single tau gene on chromosome 17. Some of the neurodegenerative disorders designated as tauopathies are linked to specific abnormalities in the tau gene affecting the splicing ratio of 3Rtau vs 4Rtau and binding of tau to microtubules (16) . Tauopathies are characterized by accumulation of intracellular tau inclusions in the absence of amyloid pathology and also include PSP. In selected regions of PSP brain, 4Rtau isoforms appear to predominate as reported at mRNA (17) and protein (18, 19) levels. Tau gene mutations favoring the 4Rtau splicing, however, have been only rarely associated with familial PSP (20) . Instead, the tau A0 allele may represent a genetic risk factor for PSP (21) . Analysis of tau levels, phosphorylated epitopes, and tau isoform content clarified some of the morphological and biochemical differences among tauopathies (13, 22, 23) . Tau may therefore serve as a potential biomarker identifying PSP and other tauopathies. Abnormal intracellular inclusions contain tau aggregated into filaments. Two kinds of tau filaments have been ultrastructurally demonstrated in PSP: straight filaments and paired helical filaments (PHFs), also seen as loosely intertwined paired filaments (24) (25) (26) . It is unclear which kinds of filaments are present in the 3 morphologically distinct tau inclusions. It is also unclear whether tau content in these filaments is biochemically diverse. A minimal diversity in tau content is suggested by the biochemical studies of PSP brain homogenates showing a uniform composition of tau in several brain regions (27) .
In the present study, we examined both tau protein content and the ultrastructure of abnormal filaments isolated from pathologically distinct PSP brain regions. Our goals were to find correlations between the morphological appearance of abnormal tau inclusions in various types of cells and (i) the ultrastructure of tau filaments in these inclusions, and (ii) the composition of tau protein.
The results of our studies suggest that the 3 kinds of PSP tau inclusions are distinct from each other in ultrastructure. Glial and neuronal inclusions also differ in the biochemical composition of tau protein. We conclude that these differences depend on the type of affected cells.
MATERIALS AND METHODS

Brain Tissue
Data on PSP and AD patients used in the present studies are listed in Table 1 . An AD patient (case 4) had moderately advanced pathological stage of AD. Frontal lobe used in our studies had 2 to 3 NFTs per 40ϫ field. Brains were obtained from brain banks at Albert Einstein College of Medicine/Montefiore Medical Center (Bronx, NY) and Mayo Clinic (Jacksonville, FL). In all cases, left hemispheres were fixed in 4% formalin and used for neuropathological examination, and right hemispheres were kept frozen at Ϫ85ЊC until used for biochemical and ultrastructural studies. Our PSP cases were typical and were not expected to show asymmetrical changes. It is, however, difficult to completely exclude the possibility that the burden of a particular lesion was different in the frozen and fixed tissue.
Primary Antibodies
Tau antibodies, their characteristics, and the location of epitopes on the tau molecule are shown in Figure 1 and 
Immunohistochemistry
Paraffin-embedded 5-m-thick sections were obtained from motor cortex and cerebellar white matter from all PSP brains. In addition, sections of frontal white matter, perirhinal cortex with amygdala, and caudate nucleus were obtained from case 1. All sections were stained with H&E, Bielschowsky, and Gallyas methods. Immunocytochemistry for tau was performed with selected antibodies (MC-1, PHF-1, CP13, Tau-1, and AT8) using standard methods and the Avidin-Biotin Vectastain kit (Vector Laboratories, Inc., Burlingame, CA). Double immunostaining was performed as described (35) using pairs of antibodies GFAP/MC-1, GFAP/PHF-1 and GFAP/AT8 and the Avidin-Biotin system. Two chromogen substrates for horseradish peroxidase included 3,3Ј-diaminobenzidine tetrahydrochloride (DAB; Sigma) and SG substrate kit (Vector SG, Vector Laboratories, Inc.). These substrates resulted in either brown (DAB) or blue (SG) precipitates. 
Isolation of Filament-Enriched Fractions
Tau filament-enriched fractions were isolated from the same regions of PSP brains as described for immunohistochemistry. The amount of frozen brain tissue available was as little as 0.3 g (caudate nucleus and perirhinal cortex) up to 2 g or more (motor cortex and white matter). Tau filaments (PHFs) were also isolated from an AD brain (frontal lobe). The isolation procedure has been described previously (36) and used with minor modifications. In brief, brain tissue was homogenized in isolation buffer A (1:10 w/v; 20 mM MES/NaOH, pH 6.8, 80 mM NaCl, 1 mM MgCl 2 , 2 mM EGTA, 0.1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride [PMSF] ) and the homogenate was centrifuged for 20 min at 27,000ϫ g. The obtained supernatant, which contained most of the soluble tau protein (nonfilamentous tau), was separated and designated as S 1 fraction. The remaining pellet was suspended in buffer B (1:10, w/ v; 10 mM MES/NaOH, pH 7.4, 0.8 M NaCl, 10% sucrose, 1 mM EGTA, and 0.2 mM PMSF) and centrifuged as above. The obtained supernatant was supplemented with sarcosyl (1%, w/ v), incubated at 4ЊC overnight and centrifuged for 2 hours (h) at 100,000ϫ g. The resulting pellet was suspended in 50 mM MES/NaOH, pH 7.2 (0.5 ml/g tissue) and designated as sarcosyl-insoluble fraction. This fraction was enriched in sarcosylinsoluble tau filaments as examined by electron microscopy. In fractions from AD, abundant twisted filaments typical of ADtype PHFs were observed.
Western Blotting
Samples of filament-enriched fractions were mixed with Laemmli buffer to obtain final concentrations of SDS (2%), ␤-mercaptoethanol (2%), and Tris/HCl, pH 6.8 (62.5 mM). Samples were boiled for 5 min, then spun for 1 min at 12,000ϫ g before separation on SDS-PAGE using 10% polyacrylamide gels. Separated proteins were electrotransferred onto nitrocellulose membranes and incubated with 5% nonfat milk in 10 mM Tris/HCl, pH 7.4, and 150 mM NaCl (TBS) to block nonspecific protein binding sites. Membranes were incubated with primary antibodies overnight at 4ЊC and then with secondary antibodies conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, CA) for 1 h at 25ЊC. Both primary and secondary antibodies were diluted in 5% milk in TBS. Specific protein signals were detected with an enhanced chemiluminescence system (ECL) from Amersham Life Science (Arlington Heights, IL).
Immunogold Labeling and Electron Microscopy
Filament-enriched fractions (10-25 l) were deposited for 5 min onto 200 mesh copper grids (Fullam, Latham, NJ) precoated with Formvar and carbon. Unfixed samples on grids were incubated for 30 min at 25ЊC in the blocking medium (phosphate buffered saline, pH 7.4 with 0.1% bovine serum albumin, 0.1% gelatin and 5% horse serum), immunolabeled as described below and then stained with 2% uranyl acetate (37) . For immunogold labeling, grids were incubated for 1 h with each of the primary and secondary antibodies. Primary antibodies were 2-to 10-fold more concentrated than that for Western blotting (Table 2) . Secondary antibodies were conjugated to 10-nm colloidal gold particles and used at 1:25 dilution (Amersham Life Science). Samples were examined using a JEOL 100CX electron microscope.
RESULTS
Characterization of PSP Cases
All 3 PSP patients clinically presented with parkinsonism, postural instability, supranuclear gaze palsy, and pseudobulbar palsy. These features were consistent with PSP, but inconsistent with mixed dementia because of fairly well-preserved cognitive functions. The diagnosis of PSP based on the clinical history was confirmed by a neuropathologic examination of autopsy material. All 3 cases followed the neuropathologic criteria for typical PSP (7) in that they had an abnormal semiquantitative distribution of NFTs and neuropil threads, especially in the basal ganglia and brainstem, and tau-positive astrocytes in the involved areas. Rare amyloid plaques typically found in PSP (38, 39) were present in cases 1 and 3 according to the expected frequency for age.
In each brain, we identified anatomical regions containing a single predominant type of pathological tau inclusion: tufted shape inclusions in astrocytes, coiled bodies in oligodendrocytes, and NFTs in neurons. In a given section, the type of inclusion was determined by using biochemical and morphological criteria. Initially, to select for tufted astrocytes, double immunocytochemistry was performed using tau and the astrocytic cell marker, GFAP. Co-localization of both markers confirmed that inclusions were of astrocytic origin. The shape of the tufted astrocytes was very characteristic, resembling that described earlier (6, 9) . Tufted astrocytes exhibited no apparent cytoplasm but had tufts of argyrophilic, long, fine radiating fibers. Tau-positive but GFAP-negative inclusions indicated cells of either neuronal or oligodendroglial origin. To differentiate these cells, the morphological appearance of inclusions was evaluated with Gallyas stain or tau immunohistochemistry. Globose or flame-like-shaped NFTs were indicative of neuronal pathology. Coiled body shape was indicative of oligodendroglia (40, 41) . A small number of tufted astrocytes were also found to be immunonegative for GFAP. In these instances, the morphology of the inclusion material was a deciding factor.
Immunohistochemistry of Tau Inclusions
Coiled Bodies: Coiled bodies were particularly prominent in both frontal and cerebellar white matter with Gallyas stain ( Fig. 2A, insertion) . They were immunoreactive with tau antibodies MC-1 ( Fig. 2A) , CP13, and AT8. Neither tau-immunoreactive astrocytes nor tau-positive neurons could be distinguished in the white matter ( Fig. 2A) , suggesting that oligodendroglial pathology was an exclusive tau pathology in these regions.
Tufted Astrocytes: Tufted astrocytes were numerous in motor and premotor cortex, caudate nucleus, nucleus accumbens, and putamen, particularly as shown on sections with Gallyas stain (Fig. 2B ). In the motor cortex, the number of tufted astrocytes varied between cases in a decreasing order (case 1 Ͼ case 3 Ͼ case 2). Tufted astrocytes were immunoreactive with tau antibodies, including MC-1 (Fig. 2C), CP13 (Fig. 2D) , and AT8. In double-stained tufted astrocytes (Fig. 2C) , a strong tau immunoreactivity was detected at the periphery of the astrocytic processes, whereas the GFAP immunoreactivity predominated in the perinuclear region. In some cells, the presence of nuclei was difficult to discern either due to staining artifact or to intrinsic nuclear loss. In motor cortex of cases 2 and 3, tufted astrocytes were interspersed with a few NFTs and coiled bodies. In all 3 PSP cases, thorn-shaped astrocytes were absent.
Neurofibrillary Tangles: NFTs were predominantly found in perirhinal cortex and anterior hippocampus. Although these NFTs were easily detected with Gallyas stain, they were less abundant than those typically seen in AD. Two kinds of NFTs could be distinguished: classic flame-like NFTs seen particularly in perirhinal cortex (Fig. 2E, F ) and globose type of NFTs found mostly in deep subcortical nuclei (Fig. 2G) . Regardless of the shape, both kinds of NFTs were immunoreactive with PHF-1, MC-1 (Fig. 2E, G) , CP13 (Fig. 2F) , and AT8, but were not immunoreactive with the Tau-1 antibody (not shown). The absence of Tau-1 immunoreactivity suggests that this epitope is blocked by phosphorylation as seen in other neurodegenerative disorders. For example, Tau-1 binding is inhibited in AD and this inhibition is considered a hallmark of neurodegeneration (42) . In perirhinal cortex, in addition to NFTs, a few coiled bodies were also detected. In the vicinity of NFTs, classical senile plaques surrounded by astrocytes were interspersed (0-1 plaque/40ϫ field) as identified using tau and thioflavin-S staining.
Ultrastructure and Labeling of Tau Filaments
The results of ultrastructural analysis are summarized in Table 3 . In the present studies, twisted filaments were defined as those displaying periodicity in width with decisive crossovers of hemi-filaments. Straight filaments were those lacking periodicity in width. In addition, a third type of filament was identified. These filaments were neither straight nor twisted and were designated as jagged filaments (see ''Tufted Astrocytes'' below). The results of immunogold labeling were compatible with immunohistochemical data (Table 3) .
Coiled Bodies: Coiled bodies were the only inclusions identified microscopically in frontal and cerebellar white matter regions (Fig. 2A) . Filament-enriched fractions isolated from these regions contained predominantly, but not exclusively, straight filaments labeled at various density with PHF-1 (Fig. 3A, C, D , F, G) and only rarely with Tau-1 antibodies (Fig. 3B, E) . These filaments were approximately 14-nm wide (n ϭ 19), but their width varied extensively from 7 to 20 nm, often within a single filament. The variations in width appeared random rather than periodic, and decisive crossovers of hemi-filaments were absent. These features were distinct from those described in AD (36) . Such morphology could result from PSP-specific or cell type-specific aggregation of tau. Most of the filaments had a smooth surface, with an occasional small bud extending from or attached to the filament proper (Fig. 3A, B, arrows) . Rarely, approximately 7-to 8-nm-wide filaments were seen in tight, parallel bundles (Fig. 3F) or loose aggregates.
Tufted Astrocytes: Tufted astrocytes were seen predominantly in the caudate nucleus of case 1 and motor cortices from all 3 cases (Fig. 2B-D) . Filament-enriched fractions isolated from these regions contained filaments that were highly heterogeneous and widely varied in width and in an overall appearance (Fig. 4) . The majority was similar to straight filaments although their surface appeared rough and irregular and their contours were jagged. The ends of filaments were blunt or splayed. In splayed filaments, fan-like ends consisted of distinct fibrils (Fig. 4A, B , E, asterisks) as seen at a higher magnification (Fig. 5A, C) . Most of the filaments had irregular, nonperiodic changes in width, which ranged from 7 to 33 nm. An average maximal width of these filaments was approximately 22 nm (n ϭ 22). Although changes in width were more regular in some filaments (Fig. 4A, F , G, arrowheads), these filaments lacked distinct crossovers and thus were not considered twisted. Since the filaments in tufted astrocyte-enriched fractions were neither straight nor twisted, they were regarded as a third type of filament and designated as jagged filaments. As an exception, a single 27-nm-wide filament was detected, which was regularly twisted at 62-nm intervals (Fig. 4I ) and thus closely resembled PHFs of AD type. This filament might have originated from the rare NFTs in the deeper cortical neurons. The filaments in tufted astrocyte-enriched fractions were consistently labeled with PHF-1, AT8, AT100, and Tau 46 but not with Tau-1 (Fig. 4B, E, I ).
Neurofibrillary Tangles: NFTs were predominantly seen in perirhinal cortex and hippocampus of case 1. Filament-enriched fractions from both regions contained the majority of regularly twisted filaments with clearly defined crossovers (Fig. 6A-E) . The twisted filaments were 17-to 33-nm wide (average maximal width of 22 nm; n ϭ 24). The twisting interval ranged from 50 to 110 nm, with an average value of 80 nm. Twisting in some exceptionally wide 27-to 33-nm filaments, however, was uncertain (Fig. 6A, insert) . The appearance of twisted filaments from perirhinal cortex (Fig. 6A, C, E) closely resembled that of AD-PHFs (Fig. 6F) . Interestingly, some of the twisted filaments were splayed into 2 or 3 fibrils (Fig. 5B, D) . A small number of straight, 13-nm-wide filaments was also identified (Fig. 6D) . The appearance of straight filaments was similar to that seen in frontal and cerebellar white matter. Both twisted and straight filaments were immunolabeled with PHF-1 (Fig. 6A-D) and AT8 (not shown), similar to those in AD (Fig. 6F ).
Tau Protein: Band Pattern
In Western blotting, PHF-1 was found to be the most sensitive of the tau antibodies used. In all regions, there were 2 major PHF-1 immunoreactive polypeptides of 64 and 68 kDa, except for perirhinal cortex and hippocampus, where an additional 60 kDa polypeptide was seen (Fig. 7A-C) . The 3-band, but not 2-band, pattern was similar to that found in samples from AD (Fig. 7C) . The Tau 46 and E-10 immunoreactivity was examined only in selected regions (Fig. 7A, B) due to a limited material. With E-10, the pattern of 2 major bands of 64 and 68 kDa was detected in all selected fractions, similar to that obtained with PHF-1. With Tau 46, besides the 64 and 68 kDa polypeptides, there were 4 additional bands detected between 45-60 kDa. These additional bands were particularly prominent in motor cortex of cases 2 and 3 ( Fig. 7B-MTR2 and MTR3) . represent tau degradation products, e.g. C-terminal fragments retaining only the Tau 46, but not the PHF-1 epitope, since both epitopes are located close to each other ( Fig. 1; Table 2 ).
Tau Protein: Variable Phosphorylation
The presence of Tau 46-positive, but PHF-1-negative, bands in only some samples suggested that phosphorylation of PHF-tau polypeptides varied among cases and regions. Such a possibility was confirmed by using phosphate-dependent tau antibodies, including Tau-1, which binds only to a nonphosphorylated epitope. Consistent with previous reports, Tau-1 showed no binding to PHFtau polypeptides in our AD samples (Fig. 7C ). In contrast, Tau-1 detected 4-6 polypeptides migrating between 45-64 kDa in most of the PSP samples (Fig. 7A-C) . These polypeptides co-migrated with Tau 46-positive bands between 45-64 kDa but not with the 68 kDa band, which was Tau 46-positive but Tau-1-negative. The extent of immunoreactivity with Tau-1 differed among the regions. For example, motor cortex and hippocampus of case 1 (Fig. 7B-MTR1 and Fig. 7C-Hipp1) showed the least, and cerebellar white matter of case 3 ( Fig. 7A-Cbl3) showed the most intense binding. Although it was difficult to precisely estimate the extent of phosphorylation, the results suggest that the motor cortex of case 1 (Fig. 7B-MTR1 ) contains almost all tau phosphorylated at the Tau-1 site, whereas the motor cortex (Fig. 7B-MTR3 ) and cerebellar white matter of case 3 ( Fig. 7A-Cbl3) contain only a small fraction of tau phosphorylated at this site. Further comparisons made between motor cortex of the 2 most diverse cases (case 1 and case 3) clearly demonstrate that the total tau content (Tau 46 binding) is lower, but the phosphorylation is higher in Although the total PHF-tau content as estimated by Tau 46 immunoreactivity is lower in case 1 than in case 3, more protein is phosphorylated in case 1, especially at the PHF-1, AT8 and Tau-1 sites. The number of PHF-tau polypeptides detected varies depending on the antibody used from 2 (PHF-1, AT8, 12E8, AT100) to 6 (Tau 46). case 1 than case 3 (Fig. 8 ). Higher phosphorylation was particularly evident with the PHF-1 and AT8 binding. A significant inhibition of Tau-1 binding also indicated higher phosphorylation at this site. With 2 other antibodies (12E8 and AT100), the difference in phosphorylation between the cases was less pronounced. In case 1, two bands of 56 and 60 kDa were Tau-1-positive but Tau 46-negative, suggesting that they may represent tau degradation products devoid of the most C-terminal region. Alternatively, the differential binding may be due to a higher binding affinity of Tau-1 than Tau 46. DISCUSSION PSP appears to be unique among tauopathies by involving 3 types of cells in specific anatomical areas. Also, each cell pathology presents with morphologically distinct tau inclusions. These unusual features of PSP were employed in the present studies to correlate the morphology of inclusions with the tau protein content. We conclude that the morphological heterogeneity of inclusions is accompanied by the heterogeneity of tau protein at the ultrastructural and biochemical levels.
Filament-enriched fractions from regions with the predominant glial pathology displayed structural heterogeneity depending on whether they derived from regions enriched in coiled bodies or tufted astrocytes. Filaments from coiled bodies were 14-nm wide, smooth, and on average 40% thinner than those from tufted astrocytes. They resembled abnormal thin tubules (13-15-nm diameter) of coiled bodies described in immunoelectron microscopy studies by Arima et al (41) . In comparison, filaments isolated from regions enriched in tufted astrocytes had uneven jagged surface and were as wide (22 nm) as PHFs in AD. Previous studies described either 15-nm-wide, straight filaments occasionally narrowing to 9 nm without evidence of periodicity (43), 15-to 20-nmwide, straight tubular structures immunoreactive for tau as seen in GFAP-positive cells (44) , or 18-22-nm-wide, straight filaments of tubular appearance (45) . Such filaments appear to share similarity with our jagged filaments. The fine ultrastructure of jagged filaments was uncertain. If jagged filaments were indeed made of 2 helically twisted filaments, as are those in AD, the twisting was haphazard and lacked regular periodicity or distinct crossovers. Furthermore, jagged filaments appeared to consist of multiple thin fibrils arranged parallel to the long axis, particularly prominent at splayed ends. A similar dissociation into fibrils has rarely been noted in PHFs from AD, but is seen more frequently in filaments from other disorders, e.g. CBD (46, 47) . In studies of PSP filaments, cross-sectional views revealed the presence of 6 or more protofilaments (45) . On the other hand, it is unlikely that jagged filaments resulted from simple pairing of straight filaments from coiled bodies. Jagged filaments were thinner than 2 straight filaments (e.g. 22 nm vs 28 nm) and they were not smooth. Since jagged filaments resembled neither PHFs of AD nor smooth straight filaments from coiled bodies, they were considered a unique third type of filament in PSP. They also differed from filaments found in other disorders involving glia, e.g. CBD, by displaying only minimal twisting and 22-nm width rather than 29-nm width (46) . The estimation of mass per unit length of filaments using scanning transmission electron microscopy will be necessary to determine the regional and disease-specific characteristics of PSP filaments.
Both straight and jagged filaments resolved into 2 PHF-1 immunoreactive polypeptides migrating at 64 kDa and 68 kDa. The double-band pattern was similar to that reported by Vermersch et al (27) and others (48) for most of PSP anatomical areas except for hippocampus and entorhinal cortex, where an additional 60 kDa band was found. The present results indicate that besides PHF-1-positive tau species, PHF-1-negative polypeptides are also components of straight and jagged filaments. Tau antibodies against nonphosphorylated epitopes, e.g. Tau-1 and Tau 46, revealed up to 4 additional bands, migrating between 45 kDa and 60 kDa. The total number of tau bands differed between cases and regions, but we failed to demonstrate any consistent difference in the tau content between smooth and jagged filaments. Moreover, our preliminary analysis showed that both filaments contained similar isoforms of tau, which expressed predominantly, but not exclusively, exon 10, with or without exon 2 and lacking exon 3 (case 1, not shown). We conclude that the diversity of tau at the PHF-1 epitope has no apparent effect on the ultrastructure of filaments. Studies of tau assembly in vitro using nonphosphorylated recombinant tau (49) and phosphorylated species of bovine brain tau (50) reached a similar conclusion based on the ultrastructural similarity between assembled and authentic PHFs. Further studies will determine whether phosphorylation plays only a secondary role in the formation of tau filaments in neurodegenerative disorders. It is still unclear what are the factors responsible for ultrastructural heterogeneity between smooth and jagged filaments. Since these filaments originated in different cell types, it is possible that the type of cell is one of the determining factors. Both oligodendrocytes and astrocytes contain tau protein (51, 52) and may differ in the metabolism of tau and/or in factors stimulating aggregation of tau in pathological conditions. In studies of tau assembly in vitro, stimulatory compounds (49, 53) as well as unknown factor (55) were able to determine ultrastructure of filaments.
The variability in phosphorylation of tau among regions and cases was unexpected, especially considering the similarity of the clinical history and postmortem delay. The motor cortex from 2 cases (case 1 and case 3) was most diverse. It was rich in tufted astrocytes and displayed the absence of morphological or immunohistochemical differences. In spite of differential phosphorylation of tau at PHF-1, AT8, 12E8, AT100, and Tau-1 epitopes in these cases (Fig. 7) , both contained similar jagged filaments (compare Fig. 4A with 4G ). These results emphasize an apparent lack of correlation between the ultrastructure of jagged filaments and the phosphorylation state of tau. However, the underlying reason for differential phosphorylation of tau among cases and regions remains unclear.
Similar observations of tau lacking certain phosphoepitopes were made in other disorders (32, 55) , including Pick's disease (50, 56, 57) . For example, only 2 of 4 PHF-tau bands were found to be PHF-1-immunoreactive in Pick's disease (50) . In PSP, a weak immunoreactivity with phospho-dependent but not phospho-independent antibodies was also noted (19) . This was attributed to normal tau in homogenates. In our studies, we examined isolated filament-enriched fractions devoid of a soluble pool of tau. Therefore, tau lacking certain phospho-epitopes cannot be attributed to contamination with normal tau protein. Moreover, such a contamination should be detected consistently in all PSP samples rather than in selected cases and regions only.
On the other hand, Iwatsubo et al probed several tauopathies, including PSP, and concluded that the widely occurring tau-positive inclusions share common phosphorylation characteristics irrespective of underlying disease or cell type (58) . Since the latter observations were based on immunostaining of tissue sections, examination of tau by immunoblotting is needed to more precisely define disease-and/or cell-dependent phosphorylation patterns. It is clear that, in addition to neurons, both astrocytes and oligodendrocytes express tau protein (51, 52) . It is uncertain whether similar neuronal kinases and phosphatase are found in these glial cells. Further study of the differential phosphorylation of tau in the tauopathies is necessary.
PHF-1 bound to a subset of tau polypeptides suggests the possibility that 2 discrete subpopulations of filaments were present. By immunogold labeling, however, all the filaments were PHF-1-positive, suggesting that only a single population of filaments was present and that both PHF-1-positive and PHF-1-negative polypeptides were inter-mixed in the same filament population. Tau-1 also showed differential binding to tau polypeptides by blotting. With Tau-1, however, we failed to detect any significant immunogold labeling, suggesting that this epitope, readily accessible by blotting, was inaccessible to labeling in filaments. We speculate that the inaccessibility may be due to intertwining of Tau-1-positive and Tau-1-negative polypeptides in the same filament effectively blocking this epitope from labeling. Alternatively, the density of Tau-1-positive polypeptides is below the level of detection by immunogold labeling. These results underline the importance of Western blotting in determining the phosphorylation state of PHF-tau.
In contrast to glial pathology, neuronal pathology resulted in twisted filaments. For example, filament-enriched fractions from regions involving neurons, e.g. perirhinal cortex or hippocampus, contained an abundance of twisted filaments. As in glia, some filaments splayed into distinct fibrillary components. It will be of interest to determine the mass of the individual fibrils by scanning transmission electron microscopy. The maximal and minimal widths of these filaments, as well as their regular 80-nm interval of twisting, indicate that ultrastructurally these filaments closely resemble PHFs of AD. They resemble PHFs of AD also by immunoblotting as demonstrated by the presence of 3 major tau bands of 60, 64, and 68 kDa, similar to those described for AD. We speculate that PHFs from PSP and AD have a common ultrastructural and biochemical character. Such similarity between PSP and AD has been previously reported (27, 47) and attributed to the specific tau pathology of neurons.
As in AD, twisted PHF-like filaments of PSP were found in anatomical areas containing NFTs. Unlike AD, however, 2 types of NFTs with globose or flame-shape could be distinguished morphologically. We were unable to differentiate the tau content of these NFTs because of their co-localization. It is likely that the 2 types of NFTs contain similar tau, since filaments isolated from NFTenriched regions appear ultrastructurally homogenous.
In conclusion, the results of our studies suggest that 3 kinds of tau inclusions present in PSP are distinct from each other in ultrastructure although some overlap exists. Neuronal and glial inclusions also differ in biochemical composition. These differences may depend on cell-typespecific metabolism of tau.
